IRIS
SPAGNOLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.260
AS - Asia 512
NA - Nord America 92
SA - Sud America 67
AF - Africa 9
Totale 7.940
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.242
SG - Singapore 184
CN - Cina 147
VN - Vietnam 131
US - Stati Uniti d'America 78
BR - Brasile 41
HK - Hong Kong 22
AR - Argentina 14
MX - Messico 10
ID - Indonesia 9
AT - Austria 5
EC - Ecuador 4
CO - Colombia 3
PL - Polonia 3
RU - Federazione Russa 3
AZ - Azerbaigian 2
BD - Bangladesh 2
DE - Germania 2
IL - Israele 2
IN - India 2
IQ - Iraq 2
JP - Giappone 2
TN - Tunisia 2
VE - Venezuela 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
CA - Canada 1
CL - Cile 1
DO - Repubblica Dominicana 1
EG - Egitto 1
FI - Finlandia 1
GB - Regno Unito 1
GY - Guiana 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
ME - Montenegro 1
MU - Mauritius 1
NI - Nicaragua 1
PA - Panama 1
PK - Pakistan 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
TR - Turchia 1
UA - Ucraina 1
ZM - Zambia 1
Totale 7.940
Salva come PNG Salva come JPEG
Città #
Genoa 3.892
Genova 1.898
Vado Ligure 890
Rapallo 512
Ashburn 56
Ho Chi Minh City 51
Beijing 49
Singapore 27
Hanoi 26
Bordighera 22
Hong Kong 22
Mexico City 7
Tianjin 7
Haiphong 6
São Paulo 6
Da Nang 5
Goiânia 5
Milan 5
Can Tho 4
Turin 4
Vienna 4
Brugherio 3
Buenos Aires 3
Rome 3
Thái Nguyên 3
Baku 2
Bandung 2
Beinasco 2
Belo Horizonte 2
Biên Hòa 2
Bắc Giang 2
Bắc Ninh 2
Chennai 2
Denver 2
Jakarta 2
Mendoza 2
Moscow 2
Ninh Bình 2
Quito 2
Quảng Ngãi 2
Quận Bình Thạnh 2
San Jose 2
Tel Aviv 2
Tunis 2
Verona 2
Villasanta 2
Acolman 1
Ancol 1
Ankara 1
Annapolis 1
Asunción 1
Aswān 1
Atyrau 1
Baghdad 1
Barquisimeto 1
Barra Mansa 1
Beau Bassin-Rose Hill 1
Bekasi 1
Belo Campo 1
Belém 1
Berazategui 1
Boca Toma 1
Bogotá 1
Bologna 1
Boston 1
Brasília 1
Bucaramanga 1
Campo Novo do Parecis 1
Caracas 1
Carmópolis de Minas 1
Central de Minas 1
Curitiba 1
Diamantina 1
Doha 1
Donetsk 1
Empalme San Vicente 1
Espumoso 1
Fortaleza 1
Frankfurt am Main 1
Georgetown 1
Gobernador Virasoro 1
Greensboro 1
Guangzhou 1
Guayaquil 1
Hefei 1
Honolulu 1
Houston 1
Hải Dương 1
Igrejinha 1
Johannesburg 1
Juneau 1
Kharkiv 1
La Pintana 1
Lahore 1
Lappeenranta 1
Luanda 1
Mairiporã 1
Manado 1
Managua 1
Manchester 1
Totale 7.606
Salva come PNG Salva come JPEG
Nome #
Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 294
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 223
Analisi fenotipica e funzionale dell’infiltrato linfocitario in biopsie di metastasi di melanoma, in pazienti in terapia con farmaci a bersaglio molecolare e/o inibitori dei checkpoint immunologici 203
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 196
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. 195
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 191
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 187
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 183
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma 179
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 179
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 175
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 165
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 153
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 145
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 143
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. 142
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations [Oncotarget. 2018; 9:5691-5702]doi 10.18632/oncotarget.23204 137
Regenerative surgery for the definitive surgical repair of enterocutaneous fistula 133
Regenerative surgery for the definitive repair of a vasculitic nonhealing ulcer using platelet-derived growth factors and noncultured autologous cell suspension 132
Solar radiation as a risk factor for cutaneous melanoma: Review 128
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 124
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 121
Current State of Target Treatment in BRAF Mutated Melanoma 120
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 119
Regenerative surgery for the definitive repair of chronic ulcers: a series of 34 cases treated with platelet-derived growth factors. 118
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 117
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 116
Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors 108
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 108
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study 102
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 97
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 96
Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. 93
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 92
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 90
How to make immunotherapy an effective therapeutic choice for uveal melanoma 86
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 85
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 81
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 75
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 74
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival 72
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 70
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 70
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 69
Primary endobronchial melanoma: a case report and clinical management indications 67
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 66
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 64
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 63
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 59
Hedgehog Inhibitors beyond Clinical Complete Response in Basal Cell Carcinoma: Should i Stop or Should i Go? 57
Molecular Assessment in Patients with Melanoma: When and Why? 57
Combined robotic inguinal and iliac-obturator lymphadenectomy for stage III skin cancers: Surgical technique and preliminary results 55
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 55
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 55
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 52
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study 51
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 50
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 49
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial 49
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 49
How I perform fertility preservation in breast cancer patients 49
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 46
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors 45
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion 44
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 44
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis 44
Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study 43
Machine Learning Methods for Gene Selection in Uveal Melanoma 42
Current status and perspectives in immunotherapy for metastatic melanoma 39
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 39
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 38
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 37
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 37
mAbs targeting CTLA-4 and clinical outcomes 36
The adjuvant treatment revolution for high-risk melanoma patients 36
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 35
No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: An italian melanoma intergroup (IMI) study 34
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma 33
Binimetinib for the treatment of NRAS-mutant melanoma 32
Update on Metastatic Uveal Melanoma: Progress and Challenges 31
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 31
Treatment of metastatic uveal melanoma with intravenous fotemustine 31
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study 31
Sun exposure and melanoma prognostic factors 31
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 31
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review 30
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 29
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 28
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 28
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program 28
Uveal melanoma 26
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 26
Uveal melanoma 25
Management of immune-related adverse events during treatment with immune checkpoint inhibitors 24
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors 24
Effect of age on melanoma risk, prognosis and treatment response 23
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 23
Upcoming strategies for the treatment of metastatic melanoma 23
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib 22
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial 19
Totale 8.001
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.078
article - articoli 30.636
book - libri 0
conference - conferenze 222
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 713
Totale 63.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021207 0 0 0 0 0 14 27 35 31 48 35 17
2021/2022434 21 21 23 46 21 42 19 81 38 61 13 48
2022/2023620 49 52 6 53 112 93 4 48 89 8 98 8
2023/2024598 12 42 18 81 34 80 21 56 30 29 36 159
2024/20252.569 102 167 51 137 297 247 196 375 103 105 252 537
2025/20262.417 503 194 659 458 518 85 0 0 0 0 0 0
Totale 8.209